SGHERZA, NICOLA
 Distribuzione geografica
Continente #
NA - Nord America 1.101
AS - Asia 735
EU - Europa 681
SA - Sud America 195
Continente sconosciuto - Info sul continente non disponibili 130
AF - Africa 38
Totale 2.880
Nazione #
US - Stati Uniti d'America 1.067
IT - Italia 351
SG - Singapore 307
BR - Brasile 147
CN - Cina 126
HK - Hong Kong 107
RU - Federazione Russa 85
VN - Vietnam 66
SE - Svezia 49
DE - Germania 48
FR - Francia 43
GB - Regno Unito 31
BD - Bangladesh 28
AR - Argentina 18
IN - India 18
CA - Canada 16
CI - Costa d'Avorio 14
ID - Indonesia 14
FI - Finlandia 12
TR - Turchia 11
NL - Olanda 10
AT - Austria 9
BE - Belgio 9
MX - Messico 9
CO - Colombia 8
JP - Giappone 8
IQ - Iraq 7
PK - Pakistan 7
PL - Polonia 7
UZ - Uzbekistan 7
IE - Irlanda 6
CL - Cile 5
EC - Ecuador 5
KR - Corea 5
MA - Marocco 5
ZA - Sudafrica 5
AZ - Azerbaigian 4
JM - Giamaica 4
PE - Perù 4
TN - Tunisia 4
UA - Ucraina 4
VE - Venezuela 4
CH - Svizzera 3
CZ - Repubblica Ceca 3
EG - Egitto 3
ES - Italia 3
PH - Filippine 3
PY - Paraguay 3
TW - Taiwan 3
EU - Europa 2
NI - Nicaragua 2
SA - Arabia Saudita 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BG - Bulgaria 1
BJ - Benin 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
CU - Cuba 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
IL - Israele 1
KE - Kenya 1
KZ - Kazakistan 1
LS - Lesotho 1
LT - Lituania 1
LV - Lettonia 1
MY - Malesia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
QA - Qatar 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
Totale 2.752
Città #
Singapore 174
Ashburn 164
San Jose 137
Hong Kong 87
Milan 84
Beijing 58
Fairfield 46
Chandler 43
Council Bluffs 43
Nyköping 42
Los Angeles 33
New York 33
Bari 30
Seattle 30
Woodbridge 29
Ho Chi Minh City 24
Houston 24
Columbus 22
Santa Clara 21
Wilmington 19
Rome 18
Lauterbourg 17
Falkenstein 15
Abidjan 14
Ann Arbor 14
Cambridge 14
Boardman 13
Frankfurt am Main 13
Lawrence 13
Hanoi 12
São Paulo 12
Figino 11
Jakarta 11
London 11
Helsinki 10
Inglewood 10
Phoenix 10
Brussels 9
Buffalo 9
Dallas 9
Des Moines 9
Roxbury 8
Gesualdo 7
Moscow 7
Munich 7
Naples 7
Nuremberg 7
Tashkent 7
Atlanta 6
Brooklyn 6
Salt Lake City 6
San Diego 6
San Francisco 6
Vienna 6
Chennai 5
Chicago 5
Florianópolis 5
Johannesburg 5
Miano 5
Warsaw 5
Alcamo 4
Bitonto 4
Denver 4
Dublin 4
Florence 4
Imbersago 4
Istanbul 4
Modugno 4
Montreal 4
Orem 4
Palermo 4
Paris 4
Princeton 4
Seoul 4
Tokyo 4
Washington 4
Avellino 3
Baku 3
Belo Horizonte 3
Bengaluru 3
Birmingham 3
Bogotá 3
Bắc Ninh 3
Casablanca 3
Chiswick 3
Da Nang 3
Guangzhou 3
Hải Dương 3
Jacksonville 3
Las Vegas 3
Magé 3
Padua 3
Phú Thọ 3
Roubaix 3
Taranto 3
Verona 3
Andria 2
Aparecida de Goiânia 2
Bauru 2
Belford Roxo 2
Totale 1.645
Nome #
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 209
Challenges and opportunities of MicroRNAs in lymphomas 152
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 140
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 127
What Is New in the Treatment of Smoldering Multiple Myeloma? 112
"Hemolysis, or not hemolysis, that is the question". Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency 112
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma 102
Humoral Immune Response after anti-SARS-CoV-2 Vaccine "Booster" Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) 101
Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients 100
null 96
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor 92
Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study 91
Prospective, Case-Control Study of Serological Response after Two Doses of BNT162b2 anti-SARS-CoV-2 mRNA Vaccine in Transfusion-Dependent Thalassemic Patients 90
Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases 85
Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real-life PRIMULA study comparing bortezomib, thalidomide and dexamethasone (VTd) with VTd plus daratumumab (D-VTd) as induction therapy 80
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 76
Dasatinib first-line: Multicentric Italian experience outside clinical trials 74
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 73
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials 72
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 71
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 68
null 68
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience 64
Implications of interleukin-6 (Il-6)-blockade for severe covid-19 infection in patients with multiple myeloma 63
Strengths and Weaknesses of Different Therapeutic Strategies for the Treatment of Patients with Multiple Myeloma Who Progress After the Frontline Use of Lenalidomide: A Narrative Review 59
Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments 58
Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by “rete ematologica pugliese” 56
Latent tuberculosis infection detected by quantiferon-TB assay in patients with multiple myeloma receiving novel drugs: focus on reactivation prophylaxis in a retrospective, single-center study 55
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine is not influenced by AB0 blood group in subjects with transfusion-dependent thalassemia 50
Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry 50
Occurrence of chronic myeloid leukemia in a patient with CDC73 gene deletion: “Chance or Causality?” 47
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study 46
Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease 46
Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica Pugliese 32
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 8
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: EPICOVIDEHA‐EPIFLUEHA Report 6
Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry 6
Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS‐COV‐2—A Report From the EPICOVIDEHA/EPIRESEHA Registry 5
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients 5
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study 5
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 5
Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape 5
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study 5
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 5
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia 4
Effects of immunosuppressive and biological drugs in patients with asymptomatic monoclonal gammopathies ( MGUS or smoldering myeloma) and concomitant autoimmune disorders: Results from the real‐life MUSA study 4
Totale 2.880
Categoria #
all - tutte 12.443
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.443


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202291 0 0 0 8 6 9 14 5 5 7 21 16
2022/2023139 14 29 14 7 5 16 4 24 20 0 6 0
2023/2024186 26 31 26 8 15 28 28 5 0 0 6 13
2024/2025591 22 7 30 24 16 71 69 57 21 17 104 153
2025/20261.419 183 58 90 132 175 66 107 36 206 168 44 154
2026/2027212 83 94 35 0 0 0 0 0 0 0 0 0
Totale 2.880